ATE496024T1 - 1-(amino)indane als edg-rezeptoragonisten - Google Patents
1-(amino)indane als edg-rezeptoragonistenInfo
- Publication number
- ATE496024T1 ATE496024T1 AT03814075T AT03814075T ATE496024T1 AT E496024 T1 ATE496024 T1 AT E496024T1 AT 03814075 T AT03814075 T AT 03814075T AT 03814075 T AT03814075 T AT 03814075T AT E496024 T1 ATE496024 T1 AT E496024T1
- Authority
- AT
- Austria
- Prior art keywords
- indane
- amino
- receptor agonists
- edg receptor
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43538102P | 2002-12-20 | 2002-12-20 | |
PCT/US2003/040129 WO2004058149A2 (en) | 2002-12-20 | 2003-12-16 | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE496024T1 true ATE496024T1 (de) | 2011-02-15 |
Family
ID=32682229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03814075T ATE496024T1 (de) | 2002-12-20 | 2003-12-16 | 1-(amino)indane als edg-rezeptoragonisten |
Country Status (8)
Country | Link |
---|---|
US (1) | US7220734B2 (de) |
EP (1) | EP1581509B1 (de) |
JP (1) | JP4516430B2 (de) |
AT (1) | ATE496024T1 (de) |
AU (1) | AU2003297232B2 (de) |
CA (1) | CA2509218C (de) |
DE (1) | DE60335827D1 (de) |
WO (1) | WO2004058149A2 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005020882A2 (ja) | 2003-08-29 | 2005-03-10 | Ono Pharmaceutical Co | S1p受容体結合能を有する化合物およびその医薬用途 |
WO2005058848A1 (en) * | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
EP1772145B1 (de) | 2004-07-16 | 2011-03-23 | Kyorin Pharmaceutical Co., Ltd. | Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen |
US7241812B2 (en) | 2004-08-13 | 2007-07-10 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
JP4792400B2 (ja) | 2004-10-12 | 2011-10-12 | 杏林製薬株式会社 | 2−アミノ−2−[2−[4−(3−ベンジルオキシフェニルチオ)−2−クロロフェニル]エチル]−1,3−プロパンジオール塩酸塩又はその水和物の製造方法及びその製造中間体 |
PL1650186T3 (pl) * | 2004-10-22 | 2008-11-28 | Bioprojet Soc Civ | Nowe pochodne kwasów dikarboksylowych |
US7906549B2 (en) | 2004-12-13 | 2011-03-15 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
WO2006090849A1 (ja) * | 2005-02-25 | 2006-08-31 | Redox Bioscience Inc. | 炎症性眼表面疾患の予防ないし治療剤 |
CA2605594A1 (en) * | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | Heterocyclic compound |
WO2007043433A1 (ja) * | 2005-10-07 | 2007-04-19 | Kyorin Pharmaceutical Co., Ltd. | 2-アミノ-1,3-プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法 |
EP1988083B1 (de) | 2006-02-03 | 2014-04-02 | Taisho Pharmaceutical Co., Ltd. | Triazolderivat |
EP1988081B1 (de) | 2006-02-06 | 2012-10-17 | Taisho Pharmaceutical Co., Ltd | Bindungsinhibitor von sphingosin-1-phosphat |
TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
WO2007099423A1 (en) * | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
CA2648303C (en) | 2006-04-03 | 2014-07-15 | Astellas Pharma Inc. | 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists |
US20090324581A1 (en) | 2006-05-09 | 2009-12-31 | Daiichi Sankyo Company Limited | Heteroarylamide lower carboxylic acid derivative |
TWI396677B (zh) | 2006-08-08 | 2013-05-21 | Kyorin Seiyaku Kk | An amine alcohol derivative and an immunosuppressive agent for use as an active ingredient |
DK2058317T3 (da) * | 2006-08-08 | 2014-01-06 | Kyorin Seiyaku Kk | Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens |
JP2009269819A (ja) * | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
EP2014653A1 (de) * | 2007-06-15 | 2009-01-14 | Bioprojet | Neue Dicarbonsäurederivate als S1P1 Rezeptor Agonisten |
JP5311057B2 (ja) | 2007-08-01 | 2013-10-09 | 大正製薬株式会社 | S1p1結合阻害物質 |
BR122018001851B1 (pt) | 2007-08-13 | 2019-08-20 | Monsanto Technology Llc | Método de controle de nematódeos parasitas de plantas |
US8476305B2 (en) | 2008-02-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient |
WO2009131090A1 (ja) * | 2008-04-21 | 2009-10-29 | 旭化成ファーマ株式会社 | アミノ酸化合物 |
HUE025984T2 (hu) | 2008-05-14 | 2016-05-30 | Scripps Research Inst | Szfingozin foszfát receptor új modulátorai |
SI2913326T1 (sl) * | 2008-05-14 | 2020-11-30 | The Scripps Research Institute | Novi modulatorji sfingozinskih fosfatnih receptorjev |
HUE030424T2 (en) | 2008-07-23 | 2017-05-29 | Arena Pharm Inc | Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
BRPI0917923B1 (pt) | 2008-08-27 | 2022-04-05 | Arena Pharmaceuticals Inc | Derivado de ácido tricíclico substituído, sua composição, seu uso e processo para preparar a referida composição |
CN102361867A (zh) | 2009-01-23 | 2012-02-22 | 百时美施贵宝公司 | 在治疗自身免疫疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 |
CN102361868A (zh) | 2009-01-23 | 2012-02-22 | 百时美施贵宝公司 | 作为1-磷酸-鞘氨醇激动剂的吡唑-1,2,4-噁二唑衍生物 |
JP2012515788A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置における、s1pアゴニストとしての置換オキサジアゾール誘導体 |
US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
CN102724880B (zh) * | 2009-11-13 | 2016-09-14 | 瑞塞普托斯有限责任公司 | 1-磷酸鞘氨醇受体调节剂及手性合成方法 |
MX2012005559A (es) * | 2009-11-13 | 2012-08-23 | Receptos Inc | Moduladores heterociclicos selectivos del receptor de esfingosina 1 fosfato. |
EA035768B1 (ru) * | 2009-11-13 | 2020-08-07 | Селджин Интернэшнел Ii Сарл | Способ получения соединения, содержащего индановую группу с хиральным атомом углерода в пятичленном кольце индановой группы |
AU2010333338A1 (en) | 2009-12-14 | 2012-08-02 | Merck Patent Gmbh | Sphingosine kinase inhibitors |
EP3378854B1 (de) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Verfahren zur herstellung von (r)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)essigsäure und salzen davon |
JP2013521301A (ja) | 2010-03-03 | 2013-06-10 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1p1受容体修飾物質およびその結晶形の調製のためのプロセス |
CN103119038B (zh) | 2010-04-23 | 2016-05-04 | 百时美施贵宝公司 | 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1,2,4-噁二唑基-3-基)扁桃酰胺 |
WO2012040532A1 (en) | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
MX2021011472A (es) | 2015-01-06 | 2022-08-17 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
KR102603199B1 (ko) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염 |
CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
EP3847158A1 (de) | 2018-09-06 | 2021-07-14 | Arena Pharmaceuticals, Inc. | Verbindungen zur verwendung bei der behandlung von autoimmun- und entzündlichen erkrankungen |
AU2022291768A1 (en) | 2021-06-16 | 2023-11-30 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991015583A1 (en) | 1990-04-05 | 1991-10-17 | The American National Red Cross | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
US5585476A (en) | 1994-02-15 | 1996-12-17 | Maclennan; Alexander J. | Molecular cloning and expression of G-protein coupled receptors |
US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US5912144A (en) | 1997-04-24 | 1999-06-15 | Incyte Pharmaceuticals, Inc. | Edg-1-receptor homolog |
US6060272A (en) | 1997-05-07 | 2000-05-09 | Human Genome Sciences, Inc. | Human G-protein coupled receptors |
EP1042471B1 (de) | 1997-12-30 | 2004-08-11 | NPS Allelix Corp. | Säugertier edg-7 rezeptor homologen |
JP2002500041A (ja) | 1997-12-30 | 2002-01-08 | エヌピーエス アレリックス コーポレーション | 炎症応答に関与するリゾ脂質受容体の同定 |
WO1999046277A1 (en) | 1998-03-09 | 1999-09-16 | Smithkline Beecham Corporation | HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE |
EP1071708A4 (de) | 1998-04-23 | 2005-01-19 | Smithkline Beecham Corp | Gen der edg familie, menschliches h218 |
US6130067A (en) | 1998-05-20 | 2000-10-10 | Smithkline Beecham Corporation | Human EDG3sb gene |
CA2340334A1 (en) | 1998-08-19 | 2000-03-02 | Millenium Pharmaceuticals, Inc. | 14274 receptor, a g-protein coupled receptor related to the edg receptor family |
AU6243499A (en) | 1998-09-03 | 2000-03-27 | Millennium Pharmaceuticals, Inc. | 14275 receptor, a novel g-protein coupled receptor related to the edg receptor family |
EP1112365A2 (de) | 1998-09-11 | 2001-07-04 | Max-Delbrück-Centrum Für Molekulare Medizin | Humaner un muriner g-protein gekoppelter rezeptor edg6 (endothelial differentiation gen) und seine verwendung |
KR100926208B1 (ko) | 1998-11-20 | 2009-11-09 | 아레나 파마슈티칼스, 인크. | 사람의 오르판 g 단백질 커플링 수용체 |
US6812335B1 (en) | 1999-03-23 | 2004-11-02 | The Regents Of The University Of California | Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same |
US6323333B1 (en) | 1999-04-05 | 2001-11-27 | Smithkline Beecham Corporation | Mouse EDG1 |
WO2000060056A1 (en) | 1999-04-05 | 2000-10-12 | Smithkline Beecham Corporation | Mouse edg5 gene |
WO2000063194A1 (fr) * | 1999-04-19 | 2000-10-26 | Shionogi & Co., Ltd. | Derives de sulfonamide possedant des noyaux oxadiazole |
WO2001004139A2 (en) | 1999-07-13 | 2001-01-18 | Smithkline Beecham Corporation | Human axor29 receptor |
SE9902763D0 (sv) | 1999-07-21 | 1999-07-21 | Astra Pharma Inc | Novel receptor |
WO2001011022A1 (en) | 1999-08-05 | 2001-02-15 | Smithkline Beecham Corporation | Mouse g-protein coupled receptor edg3 |
GB9923890D0 (en) | 1999-10-08 | 1999-12-08 | Pfizer Ltd | Novel polypeptide |
WO2001027137A2 (en) | 1999-10-12 | 2001-04-19 | Smithkline Beecham Corporation | Rattus norvegicus (edg3) |
WO2002059081A2 (en) * | 2001-01-26 | 2002-08-01 | Kirin Beer Kabushiki Kaisha | Urea derivatives as inhibitors of ccr-3 receptor |
WO2003062252A1 (en) * | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
AU2003216054B2 (en) | 2002-01-18 | 2007-01-04 | Merck & Co., Inc. | Selective S1P1/Edg1 receptor agonists |
EP1575964B1 (de) * | 2002-01-18 | 2009-11-11 | Merck & Co., Inc. | "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten" |
WO2003074008A2 (en) | 2002-03-01 | 2003-09-12 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
US7309721B2 (en) | 2002-03-01 | 2007-12-18 | Merck + Co., Inc. | Aminoalkylphosphonates and related compounds as Edg receptor agonists |
JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Edg受容体アゴニストとしての1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)アゼチジン−3−カルボキシラートおよび1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)ピロリジン−3−カルボキシラート |
-
2003
- 2003-12-16 JP JP2004563642A patent/JP4516430B2/ja not_active Expired - Fee Related
- 2003-12-16 CA CA2509218A patent/CA2509218C/en not_active Expired - Fee Related
- 2003-12-16 AT AT03814075T patent/ATE496024T1/de not_active IP Right Cessation
- 2003-12-16 DE DE60335827T patent/DE60335827D1/de not_active Expired - Lifetime
- 2003-12-16 AU AU2003297232A patent/AU2003297232B2/en not_active Ceased
- 2003-12-16 EP EP03814075A patent/EP1581509B1/de not_active Expired - Lifetime
- 2003-12-16 US US10/536,730 patent/US7220734B2/en not_active Expired - Fee Related
- 2003-12-16 WO PCT/US2003/040129 patent/WO2004058149A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2003297232B2 (en) | 2010-02-04 |
JP2006511579A (ja) | 2006-04-06 |
AU2003297232A1 (en) | 2004-07-22 |
US7220734B2 (en) | 2007-05-22 |
EP1581509A2 (de) | 2005-10-05 |
CA2509218A1 (en) | 2004-07-15 |
CA2509218C (en) | 2010-09-07 |
JP4516430B2 (ja) | 2010-08-04 |
EP1581509B1 (de) | 2011-01-19 |
US20060161005A1 (en) | 2006-07-20 |
EP1581509A4 (de) | 2008-04-23 |
DE60335827D1 (de) | 2011-03-03 |
WO2004058149A3 (en) | 2004-09-16 |
WO2004058149A2 (en) | 2004-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60335827D1 (de) | 1-(amino)indane als edg-rezeptoragonisten | |
DE60329073D1 (de) | Edg-rezeptoragonisten | |
WO2003105771A3 (en) | 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATES AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDINE-3-CARBOXYLATES FOR USE AS EDG RECEPTOR AGONISTS | |
EP1575964A4 (de) | "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten" | |
WO2003073986A3 (en) | Aminoalkylphosphonates and related compounds as edg receptor agonists | |
WO2003074008A3 (en) | Aminoalkylphosphonates and related compounds as edg receptor agonists | |
WO2004103279A3 (en) | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists | |
WO2005032465A3 (en) | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists | |
LTPA2016016I1 (lt) | Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui | |
NO20051008L (no) | Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer | |
CY1116107T1 (el) | Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων | |
SE0200920D0 (sv) | Novel compounds | |
NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
ATE459603T1 (de) | Pyridinaminosulfonylsubstituierte benzamide als inhibitoren von cytochrom p450 3a4 (cyp3a4) | |
TW200637874A (en) | Peptides with neuropeptide-2 receptor (Y2R) agonist activity | |
BRPI0812504B8 (pt) | composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero | |
ATE433447T1 (de) | Pyrimiidinverbindungen | |
DK1735278T3 (da) | Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser | |
EA200500376A1 (ru) | Триазольные производные в качестве ингибиторов трансформирующего фактора роста (tgf) | |
UA96277C2 (en) | Benzimidazole derivatives | |
SG171471A1 (en) | New benzimidazole derivatives | |
DE602006018713D1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate | |
CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
EA200701867A1 (ru) | Хинолиноновые соединения в качестве агонистов рецептора 5-ht | |
EP1802297A4 (de) | Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |